Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells Injection (Anti CD30 CAR T Cells) in Patients With CD30+ Relapsed/Refractory Lymphoma

NCT05208853 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT05208853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05208853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells Injection (Anti CD30 CAR T Cells) in Patients With CD30+ Relapsed/Refractory Lymphoma
Lead sponsor
Zhejiang University
Phase
Phase 1
Overall status
Unknown status
Start date
February 10, 2022
Completion date
February 10, 2022
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, diffuse large b cell lymphoma, gray zone lymphoma, hodgkin lymphoma, mediastinal b-cell diffuse large cell lymphoma, nk/t cell lymphoma, peripheral t cell lymphoma, unspecified